Merck’s Quality-Of-Life Argument For Ridaforolimus Draws ODAC Tongue-Lashing
Executive Summary
The pivotal study failed to capture patient-reported outcomes data on drug-related side effects, and use of observational data to support the view that the mTOR inhibitor has a positive risk/benefit profile is “crazy,” committee members said.